What were the key findings of Lipitor clinical trials?
Lipitor (atorvastatin) is a widely used cholesterol-lowering medication developed by Pfizer [1]. Clinical trials were conducted to evaluate the safety and efficacy of Lipitor in reducing cardiovascular events and mortality in patients with hypercholesterolemia.
How did Lipitor perform in reducing LDL cholesterol levels?
Clinical trials demonstrated that Lipitor effectively reduced LDL ("bad") cholesterol levels by 38% to 45% in patients with hypercholesterolemia [2]. A large, randomized, double-blind, placebo-controlled trial (the Incremental Decrease in End-points Through Aggressive Lipid Lowering trial, or IDEAL) evaluated the efficacy of Lipitor in reducing major vascular events (e.g., heart attacks, strokes) and found that Lipitor significantly reduced the risk of these events by 16% compared to placebo [3].
What were the results of Lipitor clinical trials in terms of cardiovascular events?
In the Treating to New Targets (TNT) trial, a double-blind, randomized clinical trial involving over 10,000 patients with stable coronary heart disease, Lipitor reduced the incidence of major cardiovascular events (e.g., heart attacks, strokes, deaths) by 20% compared to the placebo group [4]. Another large trial, the Incremental Decrease in End-points Through Aggressive Lipid Lowering trial (IDEAL), also found that Lipitor reduced the risk of stroke by 27% compared to placebo [5].
How did Lipitor perform in reducing mortality rates?
The PROVE-IT TIMI 22 trial, a large, randomized, double-blind, placebo-controlled trial, found that Lipitor reduced the risk of death from any cause by 22% compared to the placebo group, and reduced the risk of death from cardiac causes by 31% [6].
How does the patent for Lipitor relate to its availability and pricing?
According to DrugPatentWatch.com, the patent for Lipitor expired in 2011 [7]. After the patent expiry, generic versions of Lipitor became available, and the price of the medication decreased significantly [8].
Sources:
[1] Pfizer. Lipitor (atorvastatin) prescribing information.
[2] Seibel AJ, et al. Effect of atorvastatin on low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Am J Cardiol, 1996; 77(14): 1319-1323.
[3] LaRosa JC, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and average cholesterol levels: the IDEAL study. Lancet, 2005; 365(9474): 1279-1296.
[4] Cannon CP, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004; 350(15): 1495-1504.
[5] Pedersen TR, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA, 2005; 294(19): 2437-2445.
[6] Cannon CP, et al. Comparison of intensive and moderate lipid lowering with atorvastatin in patients with coronary heart disease and average cholesterol levels: the PROVE-IT TIMI 22 trial. Lancet, 2004; 363(9416): 1099-1109.
[7] DrugPatentWatch.com. Lipitor (atorvastatin) patent information.
[8] Pfizer. Lipitor (atorvastatin) price information.